분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-11-14 15:47:56 , Hit : 353
 Keytruda Gets FDA Approval for Hepatocellular Carcinoma

https://www.empr.com/news/keytruda-pembrolizumab-liver-cancer-previously-treated-sorafenib-approval/article/814060/

MPR >  News >  Keytruda Gets FDA Approval for Hepatocellular Carcinoma

Diana Ernst, RPh
November 12, 2018


Keytruda is a programmed death receptor-1 (PD-1) blocking antibody
Keytruda is a programmed death receptor-1 (PD-1) blocking antibody

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and had Child-Pugh class A liver impairment. Patients (N=104) were treated with Keytruda 200mg intravenously every 3 weeks until unacceptable toxicity, investigator-assessed confirmed disease progression, or completion of 24 months of therapy; the primary efficacy measures were overall response rate (ORR) and duration of response according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by blinded independent central review.

Results showed an ORR of 17% (95% CI, 11–26), with 1% of patients having a complete response and 16% of patients having a partial response. A duration of response of ≥6 months and ≥12 months was observed in 89% and 56% of patients who responded to treatment (N=18), respectively; the median duration of exposure was 4.2 months.

Continued approval of Keytruda for HCC may be contingent upon verification and description of clinical benefit in confirmatory trials as the indication was approved under the accelerated approval pathway based on tumor response rate and durability of response.



Related Articles
Long-Term Aspirin Use May Reduce Liver Cancer Risk
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Cabozantinib Improves Survival in Advanced Hepatocellular Cancer


Keytruda, a programmed death receptor-1 (PD-1) blocking antibody, is also approved for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, and cervical cancer.

For more information visit Merck.com.







1267   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 245
1266   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 259
1265   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 264
1264   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 270
1263   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 284
1262   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 286
1261   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 294
1260   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 297
1259   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 299
1258   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 330
1257   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 330
1256   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 348
1255   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 352
  Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 353
1253   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 354
1252   Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 361
1251   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 367
1250   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 371
1249   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 374
1248   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 375

1 [2][3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN